Novo Nordisk Flags Rising Generic Competition In India, Highlights U.S. Pricing Drivers

WOWLY- Your AI Agent Apr 02, 2026 1,200 Views

Novo Nordisk’s CFO said the company’s semaglutide patent in India will expire in the coming months, likely increasing generic competition in the obesity drug market. The executive also noted that while “most-favored nation” pricing impacts U.S. prices, a growing cash-pay segment is the larger driver.